The DF/HCC Gl SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research into Gl cancer. The overall goal of the CDP is to nurture the success of talented new researchers in Gl cancer. By providing research support and exposure to the Gl SPORE investigators, we hope to promote the independent research careers of junior faculty. Moreover, the SPORE CDP strives to attract minority and female investigators to the field of Gl cancer. The investigators assembled in the DF/HCC Gl SPORE have a substantial record in mentorship of junior faculty working in Gl cancer research. The Gl SPORE CDP has established a formal process for the identification, selection, and mentoring of individuals pursing careers in the study of basic, clinical, and population science-based aspects of Gl cancer. The CDP Governance and Review Committee, led by outstanding senior mentors across BWH, MGH, DFCI, and BIDMC, direct a program that ensures optimal selection, support, and oversight of the Gl SPORE CDP. Over the past funding cycle, the CDP has selected, funded, and mentored 15 talented young investigators in Gl cancer who have made exceptional career development as well as substantial contributions to the field of Gl cancer.
The Specific Aims of the Career Development Program are: 1. Establish a system to identify promising young investigators seel

Public Health Relevance

Career development of young faculty is vital to the continued progress in reducing the burden of Gl cancer. The DF/HCC Gl SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research to focus on key issues in Gl cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-07
Application #
8933248
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Agarwal, Rajeev K
Project Start
2007-04-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$100,267
Indirect Cost
$60,788
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Russo, Mariangela; Siravegna, Giulia; Blaszkowsky, Lawrence S et al. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov 6:147-53
Kugel, Sita; Sebastián, Carlos; Fitamant, Julien et al. (2016) SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell 165:1401-15
Kim, Sun A; Inamura, Kentaro; Yamauchi, Mai et al. (2016) Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 114:199-206
Delaney, Susan K; Hultner, Michael L; Jacob, Howard J et al. (2016) Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 16:521-32
Mima, Kosuke; Cao, Yin; Chan, Andrew T et al. (2016) Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 7:e200
Whitley, Melodi Javid; Cardona, Diana M; Lazarides, Alexander L et al. (2016) A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 8:320ra4
Ahronian, Leanne G; Corcoran, Ryan B (2016) Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol 3:e1048405
Saha, Supriya K; Zhu, Andrew X; Fuchs, Charles S et al. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 21:594-9
Ou, Wen-Bin; Lu, Minmin; Eilers, Grant et al. (2016) Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer 115:1253-1263
Lazarides, Alexander L; Whitley, Melodi J; Strasfeld, David B et al. (2016) A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma. Theranostics 6:155-66

Showing the most recent 10 out of 481 publications